David Hay — Friday POW!: AstraZeneca (AZN)

One-line take: a single-name POW! — AstraZeneca (AZN), "We recommend a BUY on AZN" at ~$164 (~$254B cap; 52-week range $145.79–$212.71). The thesis is a ratio, not a drug: "The week's scorecard is two wins and one loss in a pipeline that has 20+ trials reading out over the next eighteen months, and that ratio is the investment thesis in a nutshell." The wins: Enhertu beat the standard of care head-to-head in a Phase 3 lung-cancer trial (DESTINY-Lung04: 14.3 vs 8.3 months progression-free, 37% lower risk of progression or death — "the definition of a standard-of-care change"), with Tagrisso real-world data reinforcing the other lung franchise. The miss: camizestrant failed its Phase 3 in hormone-driven breast cancer (Morningstar cut its estimate by $700M; a rival from Arvinas already holds the lead) — but it "does not touch the oncology franchise that is 48% of total product revenue and growing 16%." The under-noticed asset: tozorakimab for COPD (~400M patients, third-leading cause of death) — three positive Phase 3s (OBERON, TITANIA, MIRANDA) working "across all eosinophil levels," where existing biologics help only ~30% of patients; peak-sales projection raised to $5B+, FDA Priority Review, decision Q1 2027. Valuation: 24× trailing, ~14.9× forward ("undervalued vs a market P/E of 21"), 13.9× EV/EBITDA, P/S 4.16× vs >6× in 2020–21 and ~5.5× in 2025; the forward P/E is "near its lowest level in a decade" and "the last time both metrics were simultaneously near these lows was 2016 to 2017," before a re-rating took the London line from ~£40 to over £130. Technicals are conceded: no "clear breakout from a tight trading range that is our preferred price action pattern," but "its prior three corrections over this timeframe were excellent buying opportunities." Bear case: strikeouts are "the math of drug development"; US drug pricing (Medicare negotiation; US ~40% of revenue); and the $80B 2030 ambition could be revised down. Verdict: the market's pipeline skepticism "is excessive." AI noted as an underappreciated drug-discovery accelerant (the Tempus / Pathos oncology foundation-model partnership). No portfolio tables with this issue.

1. Stocks & names mentioned

Ticker	Name	Research	View	What he said	At
AZN	AstraZeneca PLC (ADR)	QT · SA · STK · FA	Positive	Pick of the Week — "We recommend a BUY on AZN" at ~$164 ("We are buyers"), down ~23% from the 52-week high of $212.71; ~$254B cap; dividend yield 1.68%. Valuation: 24× trailing P/E but "just 14.9x the 2026 estimates" — "undervalued vs a market P/E of 21" — and 13.9× EV/EBITDA on $14.2B operating cash flow (FCF $11.7B); forward P/E "near its lowest level in a decade," P/S 4.16× vs >6× in 2020–21 and ~5.5× in 2025, a ~40% dip from the 23–25× forward peaks; both metrics last this low in 2016–17, before a re-rating from ~£40 to over £130. The engine: 6% constant-currency growth on a $61B base converting to 11% core EPS growth at 81% gross margins; oncology 48% of product revenue, +16%; 20+ Phase 3 readouts in 18 months; 16 positive pivotal trials in 2025; the $80B 2030 revenue ambition (Citi: achievable "without a mega-acquisition," pipeline "best-in-sector"). This week: Enhertu's DESTINY-Lung04 head-to-head win (14.3 vs 8.3 months PFS, 37% risk reduction) — "the definition of a standard-of-care change" — vs the camizestrant Phase 3 failure (Morningstar −$700M): "two wins and one loss… that ratio is the investment thesis in a nutshell." Tozorakimab (COPD): three positive Phase 3s across all eosinophil levels, peak sales raised to $5B+, Priority Review with a Q1 2027 decision. Bear case, argued: more strikeouts are "simply the math of drug development"; US drug pricing (~40% of revenue, Medicare negotiation); the $80B target needs things to keep going right. Technicals: steady five-year up-trend but no tight-range breakout; "prior three corrections… were excellent buying opportunities." Rebuttal: the skepticism priced in "is excessive." Next earnings November 6, 2026. No portfolio tables published with this issue.	read ↗
TEM	Tempus AI	QT · SA · STK · FA	Neutral	Referenced only — AZN's partner (with Pathos) in building "the largest multimodal foundation model in oncology," which the house calls "the most strategically significant" of AZN's AI commitments, with commercial impact "probably at least a few years away." No view, valuation or recommendation on Tempus shares.	read ↗
Pathos	Pathos AI (private)	—	Neutral	Referenced only — the second partner (with Tempus) in AZN's oncology foundation-model effort; named as part of AZN's "direct investment in the data infrastructure that could compress drug discovery timelines." No view expressed.	read ↗
ARVN	Arvinas	QT · SA · STK · FA	Neutral	Named only as the competitor — "a rival drug from Arvinas has already won approval in this same indication and now holds the lead position," which makes AZN's camizestrant Phase 3 failure in hormone-driven metastatic breast cancer "sting slightly more." No view on Arvinas shares.	read ↗

"View" is Haymaker's stance in this post. AZN is the only name rated — a single-security deep dive; TEM, Pathos and ARVN are rowed Neutral as partner/competitor references. The prior healthcare-sleeve names (DGX, MDT, GILD, INCY) are not named in this post. Referenced only (not rowed): the drugs — Enhertu, Tagrisso, Imfinzi, Datroway, Tezspire, camizestrant, tozorakimab; the trials — DESTINY-Lung04, OBERON / TITANIA / MIRANDA; CEO Pascal Soriot; Citi (pipeline "best-in-sector"), Morningstar (−$700M camizestrant estimate), the FDA and Medicare; Bloomberg (the charts). This edition published no Buys / Trims-Holds tables. Research: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis.

2. Talking points

The frame — a discount created by three setbacks

AZN "is running the most productive large-cap pharmaceutical pipeline in the world right now," yet trades ~$164, 23% off its high, "despite H1 2026 core EPS growing 11%, guidance reaffirmed, and a $80 billion 2030 revenue ambition."
"The discount has been created by three specific setbacks in three months, all manageable within the context of 20-plus Phase 3 readouts expected in the next 18 months. We are buyers."
"At basically 15x this year's consensus earning estimate on 11% core EPS growth… the stock is where investors who understand the pipeline get paid for patience."

This week's data — two wins and a miss

Enhertu (Sep 14): head-to-head Phase 3 win in a lung-cancer subset — 14.3 vs 8.3 months to progression, a 37% cut in risk of progression or death. "The drug that doctors currently reach for in this setting is now demonstrably inferior to Enhertu. That is the definition of a standard-of-care change."
Tagrisso reinforced by real-world evidence: patients who stopped treatment early were "more than twice as likely to see their cancer return."
Camizestrant failed its Phase 3 in hormone-driven metastatic breast cancer; Morningstar cut its long-term estimate by $700M, and Arvinas' rival drug already holds the lead — but the failure "does not touch the oncology franchise that is 48% of total product revenue and growing 16%."
"The week's scorecard is two wins and one loss… and that ratio is the investment thesis in a nutshell."

The $80 billion question

CEO Pascal Soriot has reiterated the $80B 2030 ambition on every call, explicitly one that "assumes successes and setbacks"; it implies ~30% revenue growth over four years vs 18% compounded 2020–2025 — "ambitious but plausible if the pipeline performs."
Citi calls the pipeline best-in-sector and able to beat the target "without a mega-acquisition"; management sees >$10B peak risk-adjusted revenue from new medicines.
Diversity is the risk control: oncology, rare disease, cardiovascular, respiratory — "no single setback blows up the investment case."

AI — an underappreciated accelerant

The Tempus / Pathos partnership to build "the largest multimodal foundation model in oncology" is AZN's most strategic AI commitment, though "the commercial impact is probably at least a few years away."
House view: pharma and biopharma "will be some of the biggest winners from AI" by accelerating discovery and approval — lower R&D costs, higher profitability; "underappreciated but likely to change as breakthrough drug announcements proliferate."

Tozorakimab — the COPD opportunity nobody is pricing

COPD affects ~400 million people and is the third-leading cause of death globally.
Three Phase 3s (OBERON, TITANIA, MIRANDA) positive in March 2026, cutting moderate-to-severe exacerbations "regardless of smoking status" or eosinophil count — the commercial breakthrough, since existing biologics work in only ~30% of patients and leave the ~40% with low eosinophils with no biologic option.
Peak sales projection raised to >$5B; NDA accepted for Priority Review, decision Q1 2027 — a drug "that could more than double the addressable biologic market for COPD."

Valuation — near decade lows on both yardsticks

24× trailing, ~14.9× forward, 13.9× EV/EBITDA on $14.2B operating cash flow; "14.9x is undervalued vs a market P/E of 21." The house is "buying the central case," not the bull case.
P/S 4.16× vs >6× (2020–21) and ~5.5× (2025); forward P/E ~40% below its 23–25× peaks. "The last time both metrics were simultaneously near these lows was 2016 to 2017, before a multi-year re-rating drove the stock from approximately £40 to over £130."

Technicals — no breakout, but good dips

Steady five-year up-trend, but "there isn't the clear breakout from a tight trading range that is our preferred price action pattern." (The chart shows price ~$165 below its moving averages, marked at ~$174 and ~$183.)
Offset: "its prior three corrections over this timeframe were excellent buying opportunities."

Arguing the other side

Strikeouts: with 20+ late-stage programs reading out, failures are "simply the math of drug development."
US drug pricing: Medicare can now negotiate directly; the US is ~40% of revenue, so compression "hits a large number."
The $80B target: if two or three more programs fail and analysts revise the ambition down, "the modest multiple… might compress even further."
Rebuttal: Enhertu plus the COPD news (on top of 16 successful late-stage trials in 2025) says the cadence "is more durable than the recent setbacks imply"; the skepticism in the price is "excessive."

The bottom line

"Investors in AZN today are buying the last decade of Pascal Soriot's strategic rebuilding" — a revenue base "large enough that no individual setback materially changes the trajectory."
"The stock is at $164 because three programs missed in three months and the market repriced the uncertainty; that repricing is the opportunity." The price "does not require the $80 billion 2030 ambition to be delivered on schedule" — only that the oncology engine keeps its cadence.
"We recommend a BUY on AZN."

3. In plain English

AZN — AstraZeneca PLC Positive

AstraZeneca is one of the world's biggest drug companies (based in Cambridge, UK), with about $61 billion of yearly sales. Nearly half of what it sells is cancer medicine — lung-cancer pills like Tagrisso and the targeted drug Enhertu — and that business is growing about 16% a year. The company also sells drugs for heart, kidney, lung and rare diseases, and it keeps an unusually large number of new drugs in late-stage testing: more than 20 big final-stage trials will report results over the next year and a half.

The stock has fallen about 23% from its high because three of those trials disappointed in three months — most recently a breast-cancer drug (camizestrant) that didn't beat existing treatment. Haymaker's point is that when you run this many trials, some will fail; what matters is the hit rate. In the same week, Enhertu beat the standard lung-cancer treatment head-to-head (patients went six months longer before their cancer worsened), which is the kind of result that changes what doctors prescribe. And a COPD drug called tozorakimab — for a common lung disease affecting about 400 million people — passed three final-stage trials and works in patients current drugs don't help; the company thinks it could sell more than $5 billion a year, and the FDA is fast-tracking its review.

The price: about 15 times this year's expected profit, versus roughly 21 times for the stock market as a whole, and near its cheapest in a decade on both profit and sales measures. The last time it was this cheap (2016–17), the London shares went on to more than triple. The risks Haymaker names: more trial failures, US drug-price pressure (America is about 40% of sales and Medicare can now negotiate prices), and the chance the company's $80 billion 2030 sales goal gets cut. The chart also lacks the clean breakout the house usually likes, though past dips in this stock have been good times to buy. Verdict: a Buy — you are paid to be patient while a large, diversified pipeline does its work.

Summary derived from the paid Haymaker newsletter (text in transcript.txt) for personal study. Not investment advice. © Haymaker / David Hay for source material.